TG Therapeutics (NASDAQ:TGTX) Shares Gap Down - Time to Sell?

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report)'s stock price gapped down before the market opened on Monday . The stock had previously closed at $26.90, but opened at $24.39. TG Therapeutics shares last traded at $24.10, with a volume of 1,692,264 shares trading hands.

Analyst Ratings Changes

Several research analysts have recently issued reports on TGTX shares. HC Wainwright reiterated a "buy" rating and issued a $49.00 target price on shares of TG Therapeutics in a research note on Wednesday, September 18th. The Goldman Sachs Group upped their price objective on TG Therapeutics from $18.00 to $20.00 and gave the company a "neutral" rating in a research report on Wednesday, August 7th. TD Cowen initiated coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price for the company. Finally, B. Riley increased their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $36.33.

TG Therapeutics Price Performance

The company has a market cap of $3.77 billion, a P/E ratio of 39.62 and a beta of 2.19. The firm's 50-day moving average is $23.51 and its two-hundred day moving average is $20.10. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The firm had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. During the same quarter last year, the firm earned ($0.34) EPS. The firm's revenue for the quarter was up 357.0% compared to the same quarter last year. Analysts anticipate that TG Therapeutics, Inc. will post 0.13 earnings per share for the current year.

Hedge Funds Weigh In On TG Therapeutics

A number of large investors have recently bought and sold shares of TGTX. Los Angeles Capital Management LLC increased its stake in TG Therapeutics by 33.7% in the third quarter. Los Angeles Capital Management LLC now owns 123,401 shares of the biopharmaceutical company's stock worth $2,886,000 after purchasing an additional 31,124 shares during the period. Principal Financial Group Inc. increased its stake in TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock worth $18,061,000 after buying an additional 725,371 shares during the period. Amalgamated Bank increased its stake in TG Therapeutics by 712.0% in the 3rd quarter. Amalgamated Bank now owns 39,528 shares of the biopharmaceutical company's stock worth $925,000 after buying an additional 34,660 shares during the period. Iridian Asset Management LLC CT boosted its position in TG Therapeutics by 20.8% in the 3rd quarter. Iridian Asset Management LLC CT now owns 47,532 shares of the biopharmaceutical company's stock valued at $1,112,000 after buying an additional 8,175 shares during the period. Finally, New York State Teachers Retirement System purchased a new stake in TG Therapeutics in the 3rd quarter valued at about $1,004,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.